Noxopharm Aiming to Bring to Market its Potential Transformative Drug in the Cancer Treatment Space

▴ Noxopharm
Noxopharm Limited has been in the limelight for its potential industry disruptive and revolutionary cancer therapy in late-stage prostate cancer, where no life-extending therapies currently exist.

Headquartered in Australia, Noxopharm Limited (ASX: NOX) is a clinical-stage drug development company that has been in the limelight for its potential industry disruptive and revolutionary cancer therapy in late-stage prostate cancer where no life-extending therapies currently exist.

With around 14 million new cases of cancer diagnosed worldwide each year, approximately 7 million patients are believed to possibly receive benefits from radiotherapy. Noxopharm is targeting this potential market opportunity with an objective to bring onboard its first-to-market, versatile, well-tolerated, effective enhancer of radiotherapy - Veyonda® which aims to restore the ability of the body’s immune system to fight and eradicate cancer.

Noxopharm has developed a well-reasoned commercial strategy - the successful launch of Veyonda® into the market if possible, in the safest, quick and least expensive way, eyeing global level collaborations and research-oriented programs.

Noxopharm has the vision to become a major drug discovery and drug development company, strongly underpinned by the encouraging outcomes from its DARRT-1 and LuPIN trials, primarily focused on prostate cancer.

Noxopharm is further pushing the boundaries to explore cancer via strategically planned new studies that are in the research and development pipeline, including a potential brain cancer treatment drug program and an early cancer stem cell drug program.

Noxopharm marked its 3rd Anniversary on the ASX (Australian Securities Exchange) in 2019. It is all set to step onto the international stage with its DARRT-2 trial in planning, presenting its clinical data at various conferences, while proactively engaging with U.S based clinicians for study development.

Noxopharm also initiated its engagement with the US FDA through the IND process, which is a regulatory requirement to carry out clinical studies in the US. Moreover, the Company has lodged 6 patent families around Veyonda® and has received funding in excess of $A30 million through capital raising programs over the past three and a half years since its public listing.

Noxopharm’s clinical and scientific teams, executive management and Board of Directors have been the backbone to its success so far. The Company has established a strong alliance with prominent experts in the prostate cancer field from both Australia and U.S., providing expert guidance on the clinical development of Veyonda® and the prospects to further build on these vital relationships and potential collaborations along the way to market approval.

Tags : #newdrug #prostatecancer #noxoform #medicircle

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

China ropes in more countries for its COVID-19 vaccine trialsSeptember 29, 2020
Antarctica is still free of Covid-19. Can it stay that way?September 29, 2020
Over 200 travellers from India barred from Dubai flight over invalid Covid-19 testsSeptember 29, 2020
Netherland focuses on more stricker rule to comabt COVID-19 September 29, 2020
WHO aims to provide 120 Million rapid Coronavirus tests for poorer statesSeptember 29, 2020
UN chief on 1 Million COVID-19 deathsSeptember 29, 2020
Bahrain reports 585 Covid-19 cases, 777 recoveriesSeptember 28, 2020
Bringing hepatitis C testing and treatment to underserved communities in MadridSeptember 28, 2020
Polish doctor recovers from severe COVID-19 through rehabilitationSeptember 28, 2020
WHO supports rehabilitation of COVID-19 and other patients in UkraineSeptember 28, 2020
WHO work with migrant camps in Greece September 28, 2020
US employers being sued for COVID-19 infection spread September 28, 2020
Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Highly effective antibodies identified, may lead to passive COVID-19 vaccineSeptember 26, 2020
Europe has a lot of work to do to prevent COVID-19 transmission :WHOSeptember 26, 2020
Two million Coronavirus deaths : WHO September 26, 2020
Johnson & Johnson COVID-19 vaccine produces strong results September 26, 2020
New York to permanently switch to outdoor dining amid pandemicSeptember 26, 2020
WHO gave blessing for Coronavirus vaccine emergency use programme: ChinaSeptember 26, 2020
US surpasses 7 Million Coronavirus casesSeptember 26, 2020